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Dear Colleagues,
The key challenge in the treatment of diabetes 
remains the optimization of pharmacological therapy, 
which has been recently referred as ”individually tailo-
red therapy” but still its primary goal is to reduce the 
risk of development and progression of the disease. 
However, besides the search for new ideal diabetes 
drugs, the equally important problem is the effective 
and safe use of available diagnostic and therapeutic 
tools, minimization of adverse drug reactions, increa-
sing knowledge about the disease and its acceptability, 
adherence to recommendations and, consequently, 
improvement of quality of life of patients with diabetes.
Considering the above, I would like to draw your 
attention to two of many interesting articles published 
in the last issue of Clinical Diabetology: the paper 
presenting an interesting case of using the “old” drug, 
pioglitazone, on the one hand and the article discussing 
new possibilities of insulin therapy with ultralong-acting 
insulin glargine 300 U/mL (Gla-300) on the other hand. 
The case study presents pioglitazone therapy in a pa-
tient with type 2 diabetes mellitus with poor glycaemic 
control and elevated transaminase levels in course of 
non-alcoholic fatty liver disease (NAFLD). Pioglitazone 
therapy resulted in significant improvement reflected 
by better glycaemic control and decreased liver enzy-
me activity. It is interesting to point out the possible 
benefits of using pioglitazone in the treatment of type 2 
diabetes, because this drug, introduced in the United 
States in 1999 and in Europe a year later, is still very rarely 
used, mainly due to adverse effects of thiazolidinedione 
class (which it belongs to) and relatively short time since 
it has been launched into the Polish pharmaceutical 
market. On the other hand, an article in the pharma-
ceutical industry news section, describes insulin glargine 
300 U/mL, next (after insulin degludec) ultralong-acting 
insulin analogue. This article shows new opportunities 
for basal insulin therapy to achieve lower blood glucose 
fluctuations and to reduce the risk of hypoglycaemia. 
Less fluctuation in blood glucose level, as shown by 
numerous studies, have been implicated in the reduction 
of vascular damage, which reduces the risk of vascular 
complications of diabetes and consequently decreases 
the costs of treatment and improves the quality of life. 
As with insulin degludec, the added benefit is reducing 
the incidence of hypoglycaemia, including episodes of 
nighttime or severe hypoglycaemia that are particularly 
dangerous because patients are often unaware of them 
and cannot take appropriate corrective measures, which 
is associated with direct threat to life, but also in the 
long term leads to brain damage, cognitive function 
decline and accelerated development of dementia, 
especially in patients with type 2 diabetes.
I invite you to read and at the same time to actively 
contribute to our journals, Clinical Diabetology and 
Diabetologia Praktyczna, by submitting interesting 
papers and comments on topics discussed.
Editor-in-Chief
Prof. Janusz Gumprecht

